Abstract
Purpose of review: To discuss advances in our understanding of β cell heterogeneity and the ramifications of this for type 1 diabetes (T1D) and its therapy.
Recent findings: A number of studies have challenged the long-standing dogma that the majority of beta cells are eliminated in T1D. As many as 80% are present in some T1D subjects. Why don't these cells function properly to release insulin in response to high glucose? Other findings deploying single cell "omics" to study both healthy and diseased cells - from patients with both T1D and type 2 diabetes (T2D) - have revealed cell subpopulations and heterogeneity at the transcriptomic/protein level between individual cells. Finally, our own and others' findings have demonstrated the importance of functional beta cell sub-populations for insulin secretion.
Summary: Heterogeneity may endow beta cells with molecular features that predispose them to failure/death during T1D.
Recent findings: A number of studies have challenged the long-standing dogma that the majority of beta cells are eliminated in T1D. As many as 80% are present in some T1D subjects. Why don't these cells function properly to release insulin in response to high glucose? Other findings deploying single cell "omics" to study both healthy and diseased cells - from patients with both T1D and type 2 diabetes (T2D) - have revealed cell subpopulations and heterogeneity at the transcriptomic/protein level between individual cells. Finally, our own and others' findings have demonstrated the importance of functional beta cell sub-populations for insulin secretion.
Summary: Heterogeneity may endow beta cells with molecular features that predispose them to failure/death during T1D.
Original language | English |
---|---|
Article number | 112 |
Journal | Current Diabetes Reports |
Volume | 18 |
Issue number | 11 |
Early online date | 24 Sept 2018 |
DOIs | |
Publication status | Published - Nov 2018 |
Keywords
- beta cell
- type 1 diabetes
- insulin
- heterogeneity
- transcriptomics
- imaging